Research programme: membrane protein-targeting antibodies - MedImmune/MSM Protein Technologies
Latest Information Update: 29 Feb 2008
At a glance
- Originator Cambridge Antibody Technology; MSM Protein Technologies
- Developer MedImmune; MSM Protein Technologies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Bacterial infections; Viral infections
Most Recent Events
- 29 Feb 2008 Preclinical development is ongoing
- 29 Oct 2007 Cambridge Antibody Technology is integrated into MedImmune
- 17 Oct 2006 Preclinical trials in Viral infections in USA (Parenteral)